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The  amino acid  sequence  requirements  for  androgen- 
dependent  androgen  receptor  nuclear  import  were  de- 
termined  by  immunostaining  transiently  expressed full- 
length  wild  type  and  mutant  human  androgen  receptors 
( A R )  in  monkey  kidney COS cells and  measuring  tran- 
scriptional  activity by cotransfection  with  a  luciferase 
reporter  vector  in  monkey  kidney CV1 cells. Mutagen- 
esis studies  revealed  a  bipartite  nuclear  targeting se- 
quence  in  the DNA binding  and  hinge  regions  at  amino 
acids  017-633,  consisting  of  two  clusters  of  basic  amino 
acids  separated by  10  amino acids, =CYEAGMTLG@- 
KLKK. In a  series of deletion  mutants, AR NH2-terminal 
fragments  (residues  1-639  through  1-723)  displayed con- 
stitutive nuclear import, and transcriptional activity 
was  similar  to  that of the  ligand-activated  full-length 
wild  type AR. In contrast,  nuclear  import  and  transcrip- 
tional  activation  were  inhibited by  sequence  extensions 
into the steroid-binding domain (1-771). Constitutive 
nuclear  import  was  regained  in  part  by  NH,-terminal 
deletions of full-length AR.. Expression  of Mpyruvate 
kinase  chimeras  defined  a  sequence  required for pre- 
dominant  nuclear  localization as residues  580-661,  com- 
prised  of  the  second  zinc  finger  region  of  the  DNA-bind- 
ing domain,  the  17-amino-acid  putative  targeting 
sequence,  and 28 residues of  flanking  carboxyl-terminal 
sequence.  These  studies  uggest  hat  he  bipartite 
nuclear  targeting  sequence of AR includes  flanking se- 
quence  and is modulated  by  interactions  between  the 
N€&- and  carboxyl-terminal  regions. 
Selective transport of proteins  to  the  nucleus  represents a 
potential  site of regulation  unique to eukaryotic cells (1). A  key 
step  in  nuclear  import of transcription  regulatory  proteins  is 
the  activation of nuclear  targeting signals required for proteins 
to traverse nuclear pore complexes (2, 3). The first nuclear 
targeting  signal identified was that for SV40 large T antigen 
(4); a nine-amino-acid sequence of predominantly basic resi- 
dues was sufficient to direct a heterologous protein to the 
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nucleus ( 4 5 ) .  Similar  studies revealed a single domain  nuclear 
targeting  signal  in c-myc (6-8). In contrast, nucleoplasmin,  a 
histone  binding  protein,  requires two interdependent  domains 
of basic amino  acids  separated by a 10-amino-acid spacer se- 
quence  (9). 
The concept of ligand  activated  nuclear  transport (10,111 has 
persisted for certain  members of the  steroid receptor family, 
shown most  definitively for the glucocorticoid receptor (12-14). 
Studief on the  androgen receptor (AR)’ in  transiently  trans- 
fected cells support a ligand-activated transport mechanism 
(15, 16). However, endogenous AR, while nuclear  in  the  pres- 
ence of androgen, becomes undetectable  with prolonged hor- 
mone withdrawal (17, 18) due  in  part t o  an enhanced  rate of 
degradation  in  the  absence of androgen (19). Overexpression by 
transient  transfection  in  eukaryotic cells provides a high  rate of 
synthesis  to  facilitate immunocytochemical  detection in  the  ab- 
sence of androgen. 
Initial reports characterizing nuclear targeting signals of 
steroid  receptors included the two signals,  NL1  and NL2, of the 
rat glucocorticoid receptor: NL1  is a 28-amino-acid region as- 
sociated with  the DNA-binding domain and NL2 comprises the 
hormone-binding domain (13). For the  rabbit progesterone re- 
ceptor, a targeting  signal sequence in  the region of amino acids 
638-642 was homologous to  the SV40 large T antigen  targeting 
sequence, and  when deleted,  caused the progesterone  receptor 
to be cytoplasmic in the absence of hormone (20). Nuclear 
translocation  was associated with  dimerization  mediated 
through  the steroid-binding  domain. The progesterone  receptor 
nuclear  targeting  signal  was  postulated  to  reside  in two do- 
mains: a constitutive signal in  the  hinge r gion and a hormone- 
dependent  signal  in  the second zinc finger  region of the DNA- 
binding  domain  (21).  The specific residues  required for nuclear 
import of the progesterone receptor  are  as  yet unknown. Expo- 
sure of cells to  inhibitors of energy  synthesis  indicated that 
nuclear residency is dynamic with receptors  diffusing into  the 
cytoplasm and being  actively transported back  to the  nucleus 
(21). In  striking  contrast is immunocytochemical and biochemi- 
cal  evidence that  the  estrogen receptor is nuclear  independent 
of hormone status (22, 231, a concept also  supported by some 
studies on the progesterone  receptor  (20,  24, 25). 
In  this  report, we investigate  not only the  minimal sequence 
required for predominant  nuclear localization of AR, but also 
those regions required for complete nuclear  import as observed 
with wild type AFt in  the presence of androgen.  Mutagenesis 
studies  indicated that a signal sequence rich in basic amino 
kinase; IgG, immunoglobulin; PCR, polymerase chain reaction; Hsp, 
The abbreviations used are: AR, androgen  receptor; PK, pyruvate 
heat shock protein; R1881, methyltrienolone; DHT, dihydrotestoster- 
one; T, testosterone; W T ,  wild  type; N, nuclear; C, cytoplasmic. 
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acids similar  to  the  bipartite nuclear targeting  signal of nucleo- 
plasmin  was  required for predominant  nuclear localization of 
AR. It spans two exons and includes  portions of the DNA bind- 
ing  and hinge regions. Mutagenesis of the wild type  receptor 
and  analysis of chimeric proteins expressing  different regions 
of AR provided insight  into  the modulatory  effects of the NH,- 
and carboxyl-terminal domains. Transcriptional activity was 
monitored, in  addition, since nuclear  import is a requirement 
for transactivation. 
EXPERIMENTAL PROCEDURES 
Materials-The  following  cells and reagents were obtained: monkey 
kidney  COS-1 and CV-1 cells  from the American m e  Culture Collec- 
tion; Dulbecco's  modified essential medium  with  high  glucose, with or 
without phenol red from JRH Biosciences;  bovine  calf serum from  Hy- 
Clone Laboratories, Inc.;  ECL  Western blotting detection kit from Am- 
ersham Corp.; unlabeled deoxynucleotide triphosphates from Pharma- 
cia LKB  Biotechnology  Inc.; Sequenase from United States Biochemical 
Corp.; Tag polymerase from Promega; deep-Vent polymerase and T4 
DNA ligase from  New England Biolabs; restriction endonucleases from 
Life  Technologies,  Inc., Promega, and New England Biolabs; prestained 
protein molecular weight standards from Life Technologies, Inc.; W- 
OMAT-AR diagnostic x-ray film  from  Kodak;  D-luciferin  from Analytical 
Luminescence;  Immobilon  from  Millipore; buffers and chemicals  from 
Fisher, EM Science, and Sigma. 
Cell Culture and Dansfections-AR nuclear import was assessed 
immunocytochemically in COS cells transfected with wild  type or mu- 
tant AR expression vector DNA or pyruvate kinase (PK) chimeric DNA. 
COS cells  allow  for high level AR expression due to SV40 transformed-T 
antigen-induced amplification of the expression  vector. The wild type 
human AR expression vector pCMVhAR previously  described (15) con- 
tained the full-length coding sequence of human AR cloned in the 
pCMV5 expression vector containing the cytomegalovirus promoter 
(26). For determination of transcriptional activation, CV1 cells were 
used because low level  plasmid expression enhances androgen sensitiv- 
ity. Cells were plated at 0.45 x lo6 celld6-cm dish and cotransfected 
with 0.01-1 pg of wild type or mutant AR expression  vectors unless 
indicated otherwise, and 5 pg of luciferase reporter vector. The lucifer- 
ase reporter vector, kindly provided by Ronald M. Evans, the Salk 
Institute, La Jolla, CA, is under the control of the mouse mammary 
tumor virus promoter. DNA precipitates were prepared by vortexing 
wild type or mutant pCMVhAR and luciferase reporter vectors in 0.5 ml 
of  0.25 M CaCI, together with 0.5 ml of 0.28 M NaCI,  1.5 m~ Na,HPO,, 
0.05 M HEPES, pH  7.12, and incubated for  30 min at  room temperature. 
The mixture was added to the aspirated plates and  3 ml  of 10% bovine 
serum-containing media  added and the cells incubated for 4  h a t  37 "C. 
Following a 4-min treatment at room temperature with 15%  glycerol in 
10% fetal calf serum-containing media,  cells  were  placed in 0.2%  calf 
serum and  returned to the 37  "C incubator after two washes with TBS 
(0.14 M NaCI, 3 m~ KC], 1 m~ CaCI,, 0.5 m~ MgCl,, 0.9 mM Na,HPO,, 
25 m~ Tris, pH 7.4). After 24 and 48 h, media was replaced with serum- 
free media with or without the indicated concentrations of the synthetic 
androgen, methyltrienolone (R1881). Seven h after the last media 
change, cells  were harvested in 0.6  ml of lysis buffer (Ligand Pharma- 
ceuticals) and supplemented with 8 m~ MgCl,, 1 m~ dithiothreitol, and 
0.4 r m  phenylmethylsulfonyl fluoride, and either stored overnight at 
-74 "C or assayed immediately. Relative light units were determined on 
a Monolight 2010 Analytical Luminescence Laboratory luminometer 
after combining  0.4 ml  of reaction buffer (15 m~ MgCl,, 5 m~ ATP, 0.5 
mg/ml  bovine serum albumin, 15 m~ glycylglycine, pH 7.81, 100 pl of 
cell lysate, and 100 pl of 1 m~ D-luciferin injected automatically. 
Immunoblot  Analysis-COS  cells plated in 10-cm dishes were tran- 
siently transfected with 10 pg of wild type or mutant AR expression 
vector DNA using DEAE-dextran (27). Cells  were maintained in 10% 
serum, Dulbecco's modified Eagle's-H media, and for  cells expressing 
AR mutants containing the hormone-binding domain, 50 nM R1881  was 
added 24 h prior to  harvest. Forty-eight h  after transfection, cells  were 
washed in phosphate-buffered saline and harvested in 200 pl of 2% 
SDS,  10%  glycerol, and 10 m~ Tris, pH 6.8. Mercaptoethanol(4%) and 
bromphenol blue (1%) were added and the samples boiled 5 min. 
Forty-pl aliquots were analyzed by electrophoresis in 8% acrylamide 
gels as described  previously using AR52 (28) or AR32 (29) rabbit poly- 
clonal anti-peptide antisera. Protein bands were calibrated using mo- 
lecular weight markers phosphorylase b, bovine serum albumin, and 
ovalbumin. 
ImmunocytochemistryAOS cells  were transfected in two chamber 
glass slides as previously  described (15) and were either  untreated or 
treated with 100 n~ R1881 or dihydrotestosterone for  24 h,  and again in 
fresh media 1 h prior to fixation. Results were similar using either 
tide antibodies AR52 (28) or  AR32 (29), or chicken PK antibody kindly 
androgen. Expressed proteins were immunostained using AR antipep- 
provided by Chi V. Dang and Gary S. Hayward, Johns Hopkins Univer- 
sity School of Medicine.  Cells  were  fixed in 2% paraformaldehyde, 10% 
sucrose, and 0.1 M sodium phosphate, pH  7.2, treated with 5% bovine 
serum albumin in phosphate-buffered saline for  30 min, and incubated 
with AR IgG  (1-2 pg/ml) or PK  IgG (2-4 pg/ml) overnight at 4 "C. Cells 
were  washed in phosphate-buffered saline and incubated with fluores- 
cein or Texas RedR conjugated goat anti-rabbit IgG (1500; Organon 
Technika, Cochranville, PA or Molecular Probes, Inc., Eugene, OR)  for 
40-60 min at room temperature. Cells incubated with PK antibody were 
also  processed for immunofluorescence using UltraavidinTM-conjugated 
fluorescein or Texas  RedTM  (Leinco  Technologies,  Inc., St. Louis,  MO). 
Fixed cells were incubated with biotinylated goat anti-rabbit IgG 
(1:400; 60 min) followed by incubation with Ultraavidin-conjugated 
fluorescein or Texas  RedTM  (1:lOOO; 30 min) at room temperature. In an 
alternative method, cells  were  fixed in 95% ethanol for  10 min at -20 "C 
and processed  for  immunofluorescence as described  above. Results were 
similar using either fixation method with some variations; immuno- 
staining following ethanol fixation was of stronger intensity and there- 
fore  more  effective at revealing low levels of receptor. Slides were  ex- 
amined using a Nikon Optiphot 2 microscope with an EPI-fluorescence 
attachment. Each AR and PK mutant was analyzed at least  three times 
and the cells shown best represent the overall immunocytochemical 
staining  pattern. 
PCR Mutagenesis-AR mutants were constructed by  PCR mutagen- 
esis of the pCMVhAR expression vector (15) using outside primers 
containing unique restriction sites in AR and  internal primers with the 
appropriate mutations. Primers ranged in size from  15-35 nucleotides 
and were synthesized on a automated Applied  Biosystems DNA synthe- 
sizer model  394 using standard cyanoethyl phosphoramidite chemistry. 
DNA amplification was  performed using Taq or deep-Vent  polymerase. 
All PCR amplified DNA was  sequenced by the dideoxynucleotide 
method to verify error-free amplification. For  amplified regions greater 
than 200 base pairs, use of deep-Vent  polymerase with its 3' exonucle- 
ase proof-reading activity was critical to  avoid random PCR errors. PCR 
was performed in five 100-pl reactions using 1 unit of polymerasel 
reaction. Standard PCR conditions for 500-base pair regions were 1 
cycle  of 94 "C for 5 min, 56 "C for 2 min, 72  "C  for  3.5 min; 11 cycles of 
95 "C for  1.5 min, 56 "C for 2 min, 72  "C  for 3 min; and 1 cycle of 95 "C 
for  1.5  min,  56 "C for 2 min, 72  "C  for 5 min. Amplified fragments and 
enzyme-digested vectors  were  gel purified in agarose, cleaved with re- 
striction enzymes, and ligated using T4 DNAligase, typically overnight 
at 16 "C. Competent DH5 Escherichia coli  cells  were transformed and 
colonies  selected  on ampicillin containing agar plates. 
Plasmids RLPKl2 and myc317-335/PK, kindly provided by Chi V. 
Dang, Johns Hopkins  University, contained PK coding  sequence with 
and without the c-myc nuclear targeting sequence (residues 317-335) 
and were constructed from  cDNA  clones originally provided by Bruce L. 
Roberts, Integrated Genetics, MA. Both  coding  regions  were  cloned into 
the pCMV5 expression vector.  AIUPK chimeric  vectors  were constructed 
using PCR where the primers contained flanking XhoIIEcoRI restric- 
tion sites. Insertions were after amino acid 16 in PK as previously 
described (8). For insertion of the known nuclear targeting signals, 
SV40 (5) and nucleoplasmin (9), and the 617-633PK mutant, oligo- 
nucleotides of 30,52, and 57 residues, respectively, containing flanking 
XhoIIEcoRI sites, were annealed and cloned into the pCMVPK expres- 
sion  vector. 
Specific high affinity binding of [3HlR1881  was  verified using a whole 
COS  cell binding assay previously  described (27). All AR mutants con- 
taining an unaltered and complete steroid-binding domain  were  shown 
to retain high affinity [3H]R1881  binding. All carboxyl-terminal dele- 
tions, including deletion of the final exon  (A869-919), resulted in 108s of 
androgen binding. 
RESULTS 
A Bipartite  Nuclear  Targeting Signal in Human AR-Two 
methodological approaches were taken  to  investigate  the se- 
quence requirements for AR nuclear  import. Overexpression in 
COS cells allowed for immunocytochemical detection of wild 
type  and  mutant receptors. The immunucytochemical  method 
is advantageous because it can reveal incomplete nuclear 
transport  indicating  partial loss of targeting activity. The sec- 
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FIG. 1. Nuclear  transport and transcriptional activity of AR 
containing mutations in the dibasic  domain of the DNAlhinge 
region. The 919-amino-acid human AR is comprised of the NH,-termi- 
nal  transactivation region (amino  acids 1-558, open rectangle), central 
DNA-binding domain  (amino  acids  559-624, stippled area), hinge  re- 
gion (amino  acids  625-676, small open box), and  carboxyl-terminal  ste- 
roid-binding  domain  (amino  acids 677-919). Spanning  the  junctions of 
exon C (DNA-binding domain)  and  D  (hinge  region)  are two basic motifs 
(underlined) separated by 10 amino acids a t  residues 617-633. PCR 
mutagenesis  converted  basic  residues  to  methionine  in  the  full-length 
coding region as  follows: R617K618M (indicates R617 and K618 con- 
verted  to M); K632,633M; R617K618,632,633M; K630,632,633M; 
R617K618,630,632,633M. Immunocytochemical evaluation of nuclear 
transport (NT) was determined in transiently transfected COS cells 
assayed  in  the  presence of 100 n~ dihydrotestosterone or R1881. In  the 
absence of androgen, wild type  and  the five mutants showed cytoplas- 
mic perinuclear  staining.  Transcriptional  activity  (Luc)  was  determined 
in  the presence of androgen by transient  cotransfection of CV1 cells 
using 5 pg of luciferase  reporter  and 0.1 pg ofAR expression vector DNA 
as described under "Experimental Procedures." N denotes predomi- 
nantly  nuclear  staining, N>C more  nuclear  than cytoplasmic staining, 
C predominantly  cytoplasmic  staining, (+) greater  than 20-fold induc- 
tion of luciferase at 0.1 nM R1881, (-) no significant  induction of lucif- 
erase  activity  assayed a t  0.1 n~ R1881. Mutations  are shown relative  to 
the coding sequence  numbering of hAR previously reported (60). 
ond approach is measurement of transcriptional activity in 
CV1 cells, the parent cell line for COS cells, since nuclear 
transport  is a prerequisite for transcriptional activation. 
Spanning  the DNA-binding domain and hinge region of hu- 
man AR at amino acid residues 617-633 are two clusters of 
basic amino acids separated by 10 amino acids, encoded by 
exons  C and D, RKCYEAGMTLGARKLKK (Fig. 1). Based on 
homology with the  nuclear  targeting signal of nucleoplasmin 
(9), we investigated  whether  this region functions as a target- 
ing sequence of the  activated ligand-bound AR. PCR mutagen- 
esis was performed to change the 5' or 3' basic residues to 
methionine either independently and together. 
As shown in Fig. 2 A ,  unliganded AR is perinuclear in  the 
cytoplasm, and with  added  androgen, is  nuclear (Fig. 2B). Mu- 
tants R617K618M and K632,633M, shown schematically in 
Fig. 1, were  detected  in the nucleus and as cytoplasmic gran- 
ules  in  the presence of androgen  (Fig. 2, D and F) indicating a 
reduction in  nuclear  import activity relative  to wild type AR 
(Fig. 2B ). The  nature of the intensely stained cytoplasmic gran- 
ules  is  currently  under investigation. In a dose-response study, 
a  reduction in  transcriptional activity by the  partial  transport 
mutants  was noted only at very low amounts of transfected 
DNA (0.5-5 ng of DNA); however, androgen-dependent tran- 
scriptional  activity was  equivalent to or greater  than wild type 
AR with amounts of AR DNA between 10-50 ng (data not 
shown). Optimal transcriptional activity by  wild type AR occurs 
between 0.05-0.1 pg of transfected AR DNA (data not shown). 
When both right  and left domains were mutated  simulta- 
neously, i.e. R617K618,632,633M, there was no detectable 
nuclear staining  in  the presence of androgen  (Fig. W )  and no 
transcriptional activity using 0.01-1 pg of transfected DNA 
(Fig. l ) ,  indicating that both basic motifs contribute in  target- 
ing AR to the nucleus. In control studies in the absence of 
androgen, wild type AR and  the  three  transport  mutants were 
perinuclear in  the cytoplasm (Fig. 2, A, C ,  E ,  and G). 
The region of the  targeting signal  most similar  to  that of 








FIG. 2. Immunocytochemical localization of wild  type AR and 
targeting mutants expressed in COS cells in the presence  and 
absence of androgen. COS cells were  transfected  with wild type  and 
mutant AR expression vectors described in Fig. 1 using the DEAE- 
dextran precipitation method. Twenty-four h after transfection, cells 
were placed in serum-free media and 100 nM dihydrotestosterone or 
R1881 was added. Androgen was readded the  next day, 1 h prior to 
fixation. Cells were fixed and stained using the AR52 antibody de- 
scribed under "Experimental Procedures." Immunostaining is shown 
for cells either  untreated (A, C ,  E, and G )  or treated ( B ,  D, F, and H )  
with androgen for wild type AR (A and B ) ,  R617K618M (C and D), 
K632,633M (E and F ) ,  and R617K618,632,633M ( G  and H ) .  Magnifi- 
cation x 100. 
basic amino acids. Mutagenesis of 3 residues  in the  right do- 
main, K630,632,633M alone, or in combination with 
R617K618M in the left domain, resulted  in loss of androgen- 
dependent  nuclear transport. Transcriptional  activity  was un- 
detectable when assayed a t  0.1 pg of transfected AR expression 
vector DNA (Fig. 1) or over a range of transfected DNA concen- 
trations between 0.01-1 pg of DNA (data not shown). Thus, 
although replacing  2  residues in  the left or right domains did 
not eliminate nuclear transport activity, the  mutation of 3 resi- 
dues in the  right domain resulted  in loss of transport activity. 
A similar predominance of the  right basic domain was reported 
for the  bipartite signal of nucleoplasmin (9). The  results, sum- 
marized in Fig. 1, suggest the presence of a nuclear  targeting 
sequence in  human AR similar to that reported for nucleoplas- 
min, containing two basic amino acid clusters  separated by 10 
amino acids. Moreover, deletion of amino acids 615-633 con- 
taining  this  putative  targeting re ion resulted  in loss of nuclear 
transport  and transcriptional  activity  in the presence of andro- 
gen (see Fig. 6). 
Expression of wild type and  mutant AR vectors was con- 
firmed by immunoblot analysis (Fig. 3). While single or mul- 
tiple  point mutations described above did not alter the  appar- 
ent 120-kDa molecular mass of AR (Fig. 3A), major deletions 
described below resulted in  smaller forms of the receptor (Fig. 
3, B and C ) .  Approximate molecular weights of each mutant 
estimated from immunoblots are indicated. In addition, high 
affinity androgen  binding  was observed in COS cells expressing 
AR mutants that contained the full steroid-binding domain 
(data not shown). 
A Spacer Sequence Separating the Basic Motifs-The effects 
of spacing and amino acid changes in  the 10  amino acids be- 
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FIG. 3. Immunoblot analysis of wild type and mutant ARs ex- 
pressed in COS cells. Wild type  and  mutant  vectors  were v rified for 
expression  in  COS cells and for determination of apparent  molecular 
weights.  COS cells were  transfected as  described  under  "Experimental 
Procedures," and aliquots were analyzed on 8% polyacrylamide gels. 
Molecular  weights  were  estimated  relative  to the  migration of standard 
marker  proteins.  The following expressed wild type and  mutant pro- 
teins  are shown: A, pCMV5 parent  expression  vector  lacking AR se- 
quence (P5, lune 1 ); full-length pCMVhAR (WT, lune 2); R617K618M 
(RKM, lune 3); K632,633M (2KM, lune 4); R617K618,632,633M (IRKM, 
lune 5 ) ;  K630,632,633M (3KM, lune 6);  R617K618,630,632,633M 
(5RKM. lune 7); molecular  weight  markers (lune 8); deletion mutant 
lacking  amino  acids  621-625 (del, lune 9); insertion  mutant  containing 
five extra  amino  acids GPLGS a t  amino acid position 625-629 (ins, lune 
10); A622L626M ( A L M ,  lune 11 ). B, pCMV5 parent  expression vector 
lacking AR sequence (P5,  lune 1 ); full-length pCMVhAR ( WT, lune 2); 
AR1-660 (A-CID', lune 3);  AR1-723 (A-D, lune 4);AR1-771  (A-E, lune 
5 ) ;  AR1-815 (A-F, lune 6); AR1-868 (A-G, lune 7); molecular  weight 
markers (lune 8); AR1-723,K630,632,633M (A-D3KM, lune 9); AR1- 
771A199-239 (A-EATR, lune lO);AR1-815A724-771 (A-FAE, lune 11); 
ARA615-633 (lune 12);  C576A(lune 13). C ,  pCMV5 parent vector (P5, 
lune 1 ); full-length  human pCMvhAR (WT, lune 2); AR1-503 (lune 3) ;  
AR1-538 (lune 4); AR1-583 (lune 5 ) ;  AR1-617 (lune 6); AR1-639 (lune 
7): A538-614 (lune 8). 
tween the basic clusters  was investigated by analyzing three 
mutants.  Mutant A622L626M, in which alanine 622 and 
leucine  626  were  changed to methionine, displayed androgen- 
dependent  nuclear  transport  and  transcriptional activity  indis- 
tinguishable from wild type AR (Fig. 4). Insertion of five amino 
acids, GPLGS (ins), after methionine  624 did not significantly 
alter transcriptional activity and resulted in predominantly 
nuclear  staining  in  the pr sence of androgen with few cytoplas- 
mic granules  staining, suggesting that the insertion only 
slightly affected nuclear transport (Fig. 4). That one of the 
inserted amino acids was proline argues strongly against a 
strict sequence or structural  requirement of the  intervening 
region in  nuclear  targeting. Deletion of amino acid residues 
621-625 (del)  resulted  in  immunostaining like that observed 
for the insertion mutant,  with predominantly nuclear  staining 
in  the presence of androgen,  indicating that  the five-amino-acid 
deletion also only partially  disrupted  transport (Fig. 4). How- 
ever, the five-amino-acid deletion  caused complete loss of tran- 
scriptional activity, the explanation for which is  presently  un- 
clear (Fig. 4). With all three spacer mutants,  immunostaining 
was cytoplasmic and  transcriptional activity undetectable in 
the absence of androgen (not shown). Thus, none of the  muta- 
tions  within the 10-amino-acid spacer region resulted  in sig- 
nificant loss of AR nuclear  transport activity, suggesting that 
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FIG. 4. Nuclear localization and transcriptional activity of AR 
mutants in the intervening spacer region. PCR mutagenesis of 
full-length AR (wild type, WT) was performed to  create  a double point 
mutation (A622L626M), an insertion  mutation of amino  acids GPLGS 
following M624 (ins),  and  a  deletion  mutation of amino  acids  621-625 
EAGMT (del) .  Nuclear localization of wild type  and  mutant ARs was 
determined  in  transfected COS cells in  the presence of 100 n~ DHT or 
R1881, and  transcriptional  activity  in  the  presence of R1881 by cotrans- 
fection with a luciferase reporter plasmid in CV1 cells as described 
under"Experimenta1 Procedures." The immunocytochemical evaluation 
of nuclear  transport ( N T )  in  the presence of androgen  with N indicating 
predominantly  nuclear  and N>C more  nuclear  than cytoplasmic stain- 
ing. Luciferase reporter gene activity (Luc) is indicated by (+) for 
greater  than 40-fold induction of luciferase  activity a t  0.01 nM R1881, 
and (-) for no significant  induction of luciferase activity. The  mutations 
are shown relative  to  their position in  the AR sequence. 
the nuclear targeting signal is not strictly dependent on the 
number or sequence of amino acids  within this spacer region. 
Inhibition by the Carboxyl-terminal Domain-A series of de- 
letion mutants lacking  different  regions of the carboxyl-termi- 
nal domain was  created, several truncated at exon boundaries 
(see Fig. 51, to investigate the influence of this region on 
nuclear  import in  the absence of ligand binding. The  smallest 
mutant, NH,-terminal peptide AR1-503, migrated as a doublet 
between 71  and 76 kDa on immunoblots (Fig. 3C) likely due to 
differing degrees of phosphorylation.' Cytoplasmic immuno- 
staining  and absence of transcriptional activity  (summarized in 
Fig. 5) was not unexpected since AR1-503 lacks the DNA bind- 
ing, targeting signal, and steroid-binding domains. 
Mutants  that lacked the DNA-binding domain and  targeting 
signal (AR1-5381, or ones that included the  first (AR1-583) or 
both zinc finger regions of the DNA-binding domain (AR1-6171, 
but excluded the targeting region, were also predominantly 
cytoplasmic. However, punctate  nuclear  staining was  detected 
in a pattern  quite atypical for AR, indicating that,  to a limited 
extent,  these NH,-terminal polypeptides are transported to the 
nucleus independent of the  transport signal, perhaps through 
associations with other nuclear-bound proteins. Absence of 
transcriptional activity by these  truncation  mutants (Fig. 5) is 
consistent  with their lack of a complete DNA-binding domain 
(30). 
AR mutants  that extended to include the  putative  targeting 
signal, AR1-639, and beyond, AR1-660 and AR1-723, were 
nuclear  with intense  staining  and exhibited  constitutive tran- 
scriptional  activity similar  to androgen-activated wild type AR 
(Fig. 5). However, sequence extension to include exon E in  the 
steroid-binding  domain, AR1-771, or further, AR1-815 (A-F) 
and AR1-868 (A-G), resulted  in predominantly cytoplasmic im- 
munostaining  and loss of transcriptional activity (Fig. 5). When 
the inactive  signal, K630,632,633M (see Fig. l) ,  was included in 
AR1-639 (AR1-639 3KM), immunostaining  was predomi- 
nantly cytoplasmic, but some punctate nuclear  immunostain- 
ing persisted (data not shown). At transfected DNA concentra- 
tions of  0.1-1 pg of  DNA, 1-639 3KM displayed transcriptional 
activity similar to ligand-activated wild type AR. NH,-terminal 
AR fragments  that lacked the  targeting signal (1-538, 1-583, 
and 1-617, see Fig. 5) or contained a defective signal  (1-639 
Z.-X. Zhou, and E. M. Wilson, unpublished  studies. 
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FIG. 5. Nuclear localization and  transcriptional activity of carboxyl-terminal AR deletion mutants. PCR mutagenesis was performed 
to create a series of carboxyl-terminal deletion mutants, all of  which  lack  androgen binding activity. Indicated at the left are amino acid residues 
expressed in each construct, followed by letter notation to reflect the encoded exons. Full-length AR is encoded by eight exons, A-H (61), where A 
is the NH,-terminal domain, BIC the DNA-binding domain, part of D the hinge region, and D-H the steroid-binding domain.  The mutants are 
diagrammed relative to wild type AR (WT)  sequence. Nuclear transport (NT) was determined in the absence of androgen by transfection and 
immunostaining of  COS cells as described. Luciferase activity (Luc) was determined in the absence of androgen by cotransfection with a reporter 
plasmid in CV1 cells as described. Approximate  molecular weights ( M W )  were determined by immunoblot analysis (see Fig. 3). Those indicated as 
a range reflect the presence of multiple bands likely resulting from  differing degrees of phosphorylation. C denotes predcminantly cytoplasmic 
staining, N predominantly nuclear staining, C>N more  cytoplasmic than nuclear staining, and N>C more nuclear than cytoplasmic staining. 
Constitutive transcriptional activity assessed in the absence of androgen is indicated, where (+) implies activity essentially equivalent to wild type 
AR determined in the presence of androgen, and (-) implies no significant activity. The abbreviation 3" denotes mutation K630,632,633M. The 
putative nuclear targeting region is highlighted by the hatched vertical column. 
3KM)  were transported to nuclei at levels sufficient for tran- 
scriptional activation to occur  if they retained a functional DNA 
binding domain (1-639 3KM). 
The sequence requirement of the steroid-binding domain re- 
gion and the effect of receptor size in inhibiting nuclear import 
were investigated by deleting exon E (724-771) from  AR1-815 
(A-F) to form A-FAE, and by deleting residues 199-239 in the 
NH,-terminal transactivation domain  from AR1-771 (A-E) to 
form A-EATR. Interestingly, A-FAE, which encodes a protein 
about the size of the predominantly cytoplasmic A-E (106 kDa), 
displayed partial nuclear staining and absence of transcrip- 
tional activity (Fig. 5), supporting a role  for  exon E  in  transport 
inhibition and exon F in transcriptional inhibition. To test 
whether the increase in size  over that of  A-D (see above)  could 
account for transport inhibition by A-E, A-EATR, approxi- 
mately the size of the predominantly nuclear A-D, when  ex- 
pressed, was predominantly cytoplasmic. The results suggest 
that exon E  in  the steroid-binding domain has  a major  role in 
inhibiting target signal activity in the absence of androgen 
binding. Comparison of results with A-E, A-F, and A-FAE sug- 
gests, in addition, that sequences within exons E  and F con- 
tribute to  transport  and  transcriptional inhibition. 
Influence of NH,-terminal Domain Deletions-We examined 
the effects of NH,-terminal domain deletions on AR nuclear 
targeting. As diagrammed in Fig. 6, deletion of  70 amino acids 
(A14-83, including the glutamine repeat region) did not signifi- 
cantly alter androgen-dependent nuclear targeting or tran- 
scriptional activation. However, deletion mutants A14-150 or 
A14-337 of approximately 81 and  61 kDa, respectively,  were 
predominantly cytoplasmic, but with significant nuclear stain- 
ing (15-25%) in  the absence of androgen (Fig. 6). AR507-919, a 
41-kDa receptor fragment, was predominantly nuclear in  the 
absence of androgen (Fig. 6). Androgen-dependent transcrip- 
tional activity was retained by those mutants  that contained 
the  transactivation domain located between amino acids 151- 
338 (15). Thus, partial or complete deletion of the NH,-terminal 
region resulted in AR nuclear transport  in the absence of an- 
drogen despite the presence of the ligand-free, steroid binding 
region, raising the possibility that interactions between the 
NH,- and carboxyl-terminal regions block target signal activity 
in  the absence of androgen. An alternative possibility is  that 
the effects of the NH,-terminal deletions resulted from muta- 
tion-induced changes in protein folding. 
We considered whether the shortest, 41  and  61 kDa, deletion 
mutants described  above, AR507-919 and A14-337, were 
nuclear without hormone because of their size. To test this 
possibility, the defective targeting signal, R617K619,632,633M 
(see Fig. 11, was introduced into each expression vector.  Both 
expressed mutant AR proteins were  excluded  from the nucleus 
in  the absence or presence of androgen (Fig. 6) indicating that, 
at least for these two constructs, the target signal was required 
for nuclear import despite their relatively small size and loss of 
strict hormonal control of nuclear uptake. 
Chimeras of AR and Pyruvate Kinase-To establish whether 
the putative AR nuclear targeting region 617-633 was suffi- 
cient to effect nuclear transport, chimeric proteins containing 
either known nuclear targeting sequences or portions of AR 
linked to the cytoplasmic protein, PK, were expressed from the 
pCMV expression vector (Fig. 7). Rabbit polyclonal PK anti- 
serum was used to localize the chimeras in COS cells and 
revealed cytoplasmic staining of wild type PK (Fig. 8 A ) .  In 
control experiments, chimeric constructs containing nuclear 
import signals, c-mycPK (Figs. 7 and 8B) and SV40 large T 
antigedPK (Figs. 7 and SD), were  completely nuclear as pre- 
viously reported (4, 6, 8). 
The minimal putative AR targeting sequence linked to PK, 
615-633/PK, resulted in predominantly cytoplasmic  immuno- 
staining (Figs. 7  and 8E 1, indicating that  this region alone was 
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FIG. 6. Nuclear localization and 
transcriptional activity of NH,-termi- 
nal AR deletion mutants. A series of 
NH,-terminal deletion mutants was cre- 
ated by  PCR mutagenesis. On the left are 
indicated amino acid residues expressed 
or deleted, where A denotes a deletion; on 
chemical nuclear transport (NT)  deter- 
the right is summarized immunocyto- 
m DHT or R1881. N denotes predomi- 
mined in the absence and presence of 100 
nantly nuclear staining, N>C more 
nuclear than cytoplasmic staining, C>N 
more  cytoplasmic than nuclear staining, 
and C predominantly cytoplasmic stain- 
ing. Luciferase transcriptional activity 
(Luc) was determined in  the presence of 
0.1 m R1881, and  the approximate mo- 
lecular weights by immunoblot analysis. 
ported (15) or  shown in Fig. 3. x denotes 
Molecular weights were as previously re- 
the approximate position of single or  mul- 
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not sufficient to function as  an independent target sequence. In 
contrast, linking the bipartite nuclear targeting signal of 
nucleoplasmin caused varying degrees of nuclear and cytoplas- 
mic staining (Figs. 7 and 8 0 .  It was reported previously that 
this sequence was sufficient to target PK to the nucleus (9). The 
results suggest that AR and nucleoplasmin bipartite sequences 
may be less efficient nuclear import signals than  the single 
domain sequences of c-myc and SV40 T antigen.  The possibility 
that  the activity of the AR bipartite  signal is dependent on 
additional AR sequences was tested by expressing AFVPK chi- 
meras that included NH,- and carboxyl-terminal sequences 
flanking 615-633 (Fig. 7). 
Extending the AR bipartite nuclear target sequence into the 
carboxyl-terminal domain to include flanking sequence (615- 
661) or the entire steroid-binding domain (615-919, Fig. 7) 
resulted in cytoplasmic immunostaining in  the presence or ab- 
sence of androgen (Figs. 7 and 8, F-H)  as observed for  615-6331 
C N  + 
C N  + 
C>N N + 
C>N N - 
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N>C N - 
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FIG. 7. Nuclear targeting of A R P K  
chimeras. A series of  AIUF'K chimeric 
and control expression vectors was cre- 
ated in pCMV5  by inserting the regions of 
AR indicated on the right  after amino  acid 
codon 16 in PK at  an internal XhoIIEcoRI 
site. Control  vectors, mvdPK, nucleo- 










localization was determined by expres- 
sion in COS cells and immuno- 
staining using a PK antibody, where N 
denotes predominantly nuclear, C pre- 
dominantly cytoplasmic, N>C more 
nuclear than cytoplasmic staining, and 
N I C  a variable mixture of nuclear and 
cytoplasmic staining. For constructs that 
contained the full steroid-binding domain 
NsC (through amino acid 9191, immunostain- 
ing was determined in the presence and 
absence of 100 nM DHT or R1881.  PK  se- 
quence is designated by the open rectan- 
gle and includes 505 amino acids. Sixteen 
XholEcoRI insertion site (small vertical 
rectangle). The AR sequence is denoted by 
the narrow rectangles, portions of which 
the DNA-binding domain. The schematic 
in some constructs are stippled tu indicate 
at  the bottom denotes AR sequence. 
C 
N NH,-terminal PK amino acids precede the 
PK. In contrast, NH,-terminal extension to include the second 
zinc finger region of the DNA-binding domain resulted in par- 
tial nuclear import for 580-661PK  in the absence of hormone 
(Fig. &I) and for  580-919PK  upon androgen addition (Fig. 8, K 
and L ) .  The  extent of nuclear import was similar to that ob- 
served with nucleoplasmin/PK (Fig. 8C). Predominant nuclear 
staining (935%) was also observed when the entire DNA-bind- 
ing domain and flanking carboxyl-terminal sequence was in- 
cluded (amino acids 538-661) (Fig. 8N). The results suggest 
that the minimal AR sequence that promotes predominant 
nuclear staining like that observed with nucleoplasmiflK is 
amino acids 580-661, comprised of the second  zinc finger re- 
gion of the DNA-binding domain, the nuclear targeting signal, 
and 28 amino acids toward the carboxyl terminus. Essentially 
complete nuclear staining like SV40PK was observed  when the 
entire DNA-binding domain and carboxyl-terminal region 
(538-919PK) was tested  in the presence of androgen (Figs. 7 
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FIG.  8. Immunocytochemistry of AR/PK chimeras and nuclear 
import control PK vectors expressed in COS cells. The AFUF'K and 
control constructs  were  expressed  in COS cells by transient  transfec- 
tion.  Immunostaining  was  determined  in  the  absence of androgen  for 
mutants lacking the steroid-binding  domain,  and for those  constructs 
that contained the steroid-binding  domain,  in the absence  and  presence 
of 200 IIM dihydrotestosterone  or R1881. The  chimeric  proteins  were 
localized using  the  PK antibody. Shown is  the  immunostaining  for  PK 
(A), myc/PK ( B ) ,  nucleoplasminlPK ( C ) ,  SV40PK (D), 615-633PK (E), 
615-66l/F'K(F), 615-919PK (G), 615-919PKwith  androgen (H), 580- 
633PK (I), 580-661PK (J), 580-919PK ( K ) ,  580-919PK  with  andro- 
gen, 538-633PK ( M ) ,  538-66°K ( N ) ,  538-919PK (01, 538-919PK 
with  androgen.  The  constructs are  diagrammed  in  Fig. 7. Magnification 
x 215. 
and  8, 0 and P )  indicating that  the ligand-bound hormone- 
binding domain enhances, but is not essential, for nuclear 
transport. 
As shown above, androgen promoted nuclear import of  580- 
919PK and 538-919PK containing the steroid-binding do- 
main,  but not 615-919PK, which lacks the DNA-binding do- 
main (Fig. 7). Immunostaining  intensity (Fig. 8) and Western 
blot analysis  (data not  shown)  indicated that expression levels 
of the chimeric proteins were sufficient for the  measurement of 
ligand  binding affinity. However, for all three constructs, an- 
drogen binding was only slightly above background in whole 
COS cell binding assays, suggesting that  the binding  affinity 
was  near or above lo-* M, the limit of detection of the assay. 
Previous  androgen  binding studies of  AR deletion mutants  in- 
dicated that NH,-terminal deletions through amino acid resi- 
due 627 retain high affinity androgen binding activity (15). 
Mutant 580-919PK was  transported  to  the nucleus despite low 
androgen  binding similar  to  that of 615-919PK. It appears, 
therefore, that 615-919PK failed to  enter  the nucleus in  the 
presence of androgen because its lacks the second finger region 
of the DNA-binding domain. 
Role of DNA Binding  in Nuclear Targeting-Results from the 
AFUPK chimeras and AR mutants suggest that  the DNA-bind- 
ing domain contributes to nuclear targeting. To investigate 
whether loss of DNA binding  activity interferes with  nuclear 
import, we constructed three DNA-binding domain mutants, 
each of which caused loss of transcriptional activity. Deletion of 
the DNA-binding domain region, ARA538-614, resulted in par- 
tial disruption of nuclear import, but nuclear staining re- 
mained  prominent in  the presence of androgen  (diagrammed in 
Fig. 6). Changing cysteine 576 to  alanine  in  the  first zinc finger, 
C576A, showed both cytoplasmic and nuclear staining in the 
presence of androgen,  indicating some interference in nuclear 
import (Fig. 6). The  C576Amutant lacked DNA binding  activity 
when expressed as a truncated  fragment  in E. coli and assayed 
in  the mobility shift assay with androgen response element 
DNA (data  not shown). Conversion of  RRK 607-609 to M in  the 
second zinc finger region also resulted in both nuclear and 
cytoplasmic immunostaining  in  the presence of androgen.  The 
results suggest that while the DNA binding region is involved 
in  nuclear  import, DNA binding per se is not an absolute  re- 
quirement for transport activity. 
The proximity of the DNA-binding domain to  the  targeting 
signal and  its  apparent role in  nuclear  import  raised the ques- 
tion whether  the  target region could function in AR if displaced 
to  another domain. To test this hypothesis, wild type  nuclear 
targeting  residues 615-633 were inserted  into  the KpM site 
NH,-terminal of the DNA-binding domain a t  residue 504 in 
mutant R617K618,632,633M (see Fig. 1) that contained a de- 
fective targeting signal. This insertion mutant, containing a 
nuclear  targeting signal in  the NH,-terminal domain, failed to 
target to the nucleus in  the presence of androgen (data not 
shown), suggesting further that its natural orientation and 
close proximity to  the DNA-binding domain and 3"flanking 
sequence are required for its function. 
DISCUSSION 
In  the  present study, we establish  the minimal  amino acid 
sequence required to detect  nuclear  import of AR and identify 
those regions necessary for complete transport. Site-directed 
mutagenesis of human AR revealed a bipartite sequence that 
spans  the DNA binding and hinge regions encoded by exons C 
and D. The sequence, ECYEAGMTLGARKLKK, consists of 
two basic motifs that facilitate AR nuclear import. Two muta- 
tions in each domain or three  mutations in the  right basic motif 
resulted  in undetectable  nuclear  import of the receptor. In con- 
trast, single  amino acid changes or small insertions within the 
spacer region did not block nuclear  targeting,  suggesting that 
the  intervening sequence is not crucial to target signal func- 
tion. However,  usingAFUPK chimeras, the 17-amino-acid signal 
sequence alone was not sufficient to target the cytoplasmic 
protein, PK, to the nucleus. To effect partial  nuclear  transport 
like that  seen for nucleoplasminPK required the 17-amino-acid 
bipartite region together with sequences in the second zinc 
finger region of the DNA-binding domain in addition to 28 
amino acid residues of flanking carboxyl-terminal sequence, i.e. 
residues 580-661. Including the  entire DNA-binding domain, 
538-661/PK, also resulted  in predominantly nuclear immuno- 
staining. I t  cannot be distinguished, however, whether  the tar- 
get sequence extends to include the DNA-binding domain and 
the  flanking carboxyl-terminal sequence or whether  the flank- 
ing sequences impose conformational constraints necessary for 
target sequence activity. Complete transport like that observed 
for SV40PK  and wild type AR in  the presence of androgen 
required 538-919PK, including the ligand-bound AR steroid- 
binding domain. 
The  putative AR targeting signal  sequence differs from that 
of the SV40 large T antigen  in  that  the  latter consists of a single 
basic domain, PKKKRKVEF, which in  our control studies  and 
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those previously reported (4), efficiently targets PK to the 
nucleus. However, even with the SV40 T antigen targeting 
signal, the importance of protein context is evident in chimeric 
constructs of pyruvate kinase, where functional activity de- 
pends on the point of insertion (32). That these two types of 
signals, the single strong basic sequence of SV40 versus a 
weaker,  more interdependent sequence of AR, differ in  their 
effectiveness is supported by studies on the chicken progester- 
one receptor in  transient heterokaryons. The progesterone re- 
ceptor shuttles between nucleus and cytoplasm, whereas SV40 
large  T  antigen  remains nuclear, raising the possibility of a 
different type of interaction with the nuclear transport machin- 
ery (33). Bipartite  targeting sequences of the AR type appear to 
rely on cooperation among different receptor domains to facili- 
tate both nuclear/cytoplasmic shuttling  and cellular regulation 
of the  target signal. In  the case of AR and the glucocorticoid 
receptor, nuclear targeting  is regulated by steroid binding, sug- 
gesting that a conformational change secondary to ligand bind- 
ing places the targeting signal in  a functional orientation. 
One mechanism that could modulate an adjacent sequence 
and thereby influence a nuclear targeting signal is phospho- 
rylation. It was recently shown that  the  rate of nuclear import 
of SV40 large T antigen was determined by a flanking casein 
kinase I1 phosphorylation site (34,35). The targeting signal of 
S .  cerevisiae transcription factor SW15 harbors 3 nearby serine 
residues which undergo phosphorylation in  a cell  cycle-depend- 
ent  manner  and are phosphorylated when SW15 is cytoplasmic 
and dephosphorylated when nuclear (36). Phosphorylation was 
also implicated in nuclear transport  and recycling of the glu- 
cocorticoid receptor (37). While  hormone-induced phosphoryla- 
tion was not a prerequiste for nuclear transport, inhibition of 
protein phosphatases trapped  the glucocorticoid receptor in the 
cytoplasm (37). Several phosphorylation sites have been iden- 
tified in AR, one of which is in the 28-amino-acid carboxyl- 
terminal region of the nuclear targeting signal sequence (38). 
As yet, changes in phosphorylation have not been correlated 
with changes in  the function of the AR nuclear targeting signal. 
Despite a similarity in putative nuclear targeting sequences 
among the steroid receptors, little  is known about their func- 
tional dependence on other receptor domains. The estrogen 
receptor shares the arrangement of basic domains but differs 
from AR by being nuclear in  the absence of hormone  binding. 
Even the unliganded glucocorticoid receptor is observed as 
nuclear when overexpressed in  certain cell lines (39,  401, in-
voking perhaps a role for cell-specific factors. Estrogen and 
progesterone receptors apparently contain multiple targeting 
signals, including the hormone-binding domain and regions 
rich in basic amino acids, that cooperate to effect receptor 
nuclear transport (41). In contrast to AR, the estrogen receptor 
targeting signal is not inhibited by its ligand-free hormone- 
binding domain (41). In AR the 48 amino acids of exon E con- 
tributed significantly to transport inhibition. However, dele- 
tions of the NH,-terminal domain of AR resulted in  partial 
release from the nuclear transport inhibitory effect of the un- 
liganded steroid-binding domain. The estrogen receptor,  which 
is constitutively nuclear, contains a  short NH,-terminal region, 
raising the possibility that ER lacks sequences in  its NH, ter- 
minus required for transport inhibition, and that  in  the ab- 
sence of androgen, a region within the AR NH,-terminal do- 
main interacts with the steroid-binding domain to effect 
transport inhibition. In this regard, it  is noteworthy that  the 
unliganded steroid-binding domain in  the AR/€'K chimeras in- 
hibited nuclear targeting  in the absence of the AR NH,-termi- 
nal region. It is possible that in the AWPK chimera, the  tar- 
geting signal becomes inhibited by interaction with PK in  a 
manner similar to  the inhibition imposed by NH,-terminal se- 
quence in full-length AR. The apparent lowering in androgen 
binding activity by the PK chimeras suggests an intramolecu- 
lar interaction between PK and the AR steroid-binding domain. 
Specific proteidprotein interactions might be involved in  the 
inhibition or activation of nuclear transport.  The unliganded 
hormone-binding domain might be recognized as improperly 
folded, promoting an association with Hsp70 (42). ATP-depend- 
ent selective transport through nuclear pores (43-46) requires 
the interaction of import proteins with nuclear targeting sig- 
nals (43,44,47), including Hsp7O (48) and  a number of nuclear 
localization signal-binding proteins (49-51). It is noteworthy, 
therefore, that Hsp7O (39,52,53) and Hsp9O (54-56) reportedly 
interact with members of the steroid receptor family (52, 57). 
Heat shock proteins may also function as anchors or negative 
regulators (58) to inhibit  the activity of the  targeting signal. 
In conclusion, human AR contains a ligand-dependent 
nuclear targeting signal positioned immediately carboxyl-ter- 
minal of the DNA-binding  domain consisting of two basic motifs 
and adjacent sequence in  the DNA binding and hinge regions. 
The activity of the  targeting signal is regulated by the ligand- 
binding domain and by sequences within the NH,-terminal 
domain. Nuclear targeting could represent an important con- 
trol point in gene regulation, where escape  from nuclear import 
control might have a number of consequences, including possi- 
bly  oncogenic activation (59). 
Acknowledgments-We thank Jon A. Kemppainen for technical as- 
sistance and  preparing the figures, K. Michelle Cobb for maintaining 
the tissue culture cell lines, Yeqing Chen for printing the immunofluo- 
rescent pictures, and  Frank S. French for reviewing the manuscript. We 
also thank C. V. Dang  and G. S. Hayward, Johns Hopkins University, for 
PK  antibody,  C. V. Dang for  PK and  PK-myc plasmids, and R. M. Evans, 
the Salk Institute, for the luciferase  reporter  vector. 
REFERENCES 
2. Dingwall, C., and  Laskey,  R.  A. (1986) Annu. Rev. Cell Biol. 2,367-390 
1. Silver, P.  A. (1991) Cell 64, 489-497 
3. Roberts. B. (1989) Biochem.  BioDhvs.  Acta 1008.263-280 
4. Glderon, D., Richardson, W. D., Markham, A: F., and Smith, A. E. (1984) 
5. Kalderon, D., Roberts, B. L., Richardson, W. D., and Smith, A.  E. (1984) Cell 
6. Dang,  C.  V.,  and Lee, W. M. F. (1989) J. Biol. Chem. 264, 18019-18023 
7. Stone, J.,  delange, T., Ramsay, G., Jakobovits, E., Bishop, J. M., Varmus, H., 
8. Dang, C.  V.,  and  Lee, W. M. F. (1988) Mol. Cell. Biol. 8, 4048-4054 
9. Robbins, J., Dilworth, S .  M., Laskey,  R. A,, and Dingwall, C. (1991) Cell 64, 
615423 
10. Gorski, J., TOR, D., Shyamala, G., Smith, D., and Notides, A. (1968) Recent 
Prog. Horm. Res. 24 ,4540  
11. Jensen, E. V., Suzuki, T., Kawashima, T., Stumpf, W. E., Jungblut, P. W., and 
De  Sombre, E. R. (1968) Proc. Natl. Acad. Sei. U. S .  A. 69,632-638 
12. Wikstrom,  A. C., Bakke, 0.. Okret, S., Bronnegard, M., and Gustafsson, J. A. 
(1987) Endocrinology 120,1232-1242 
13. Picard, D., and  Yamamoto,  K. R. (1987) EMBO J. 6,3333-3340 
14. Picard, D., Kumar, V, Chambon,  P.,  and  Yamamoto, K. R. (1990) Cell Reg. 1, 
15. Simental, J.  A,, Sar, M., Lane, M. V.,  French,  F. S., and  Wilson, E. M. (1991) J.  
291-299 
16. Jenster, G. van der  Korput, H. A. G. M., van Vroonhoven, C., van  der Kwast, 
Biol. Chern. 266,51&518 
T. H., Trapman, J., and Brinkmann,A. 0. (1991) Mol. Endocrinol. 6,1396- 
1404 
17. Sar,  M.,  Lubahn, D. B., French, F. S. ,  and  Wilson, E. M. (1990) Endocrinology 
127,31803186 
18. Husmann, D. A,, Wilson, C. M., McPhaul, M. J., Tilley, W. D., and  Wilson, J. D. 
(1990) Endocrinology 126,2359-2368 
19. Kemppainen. J. A,, Lane, M. V., Sar, M., and Wilson, E. M. (1992) J.  Biol. 
Nature 311,3348 
39,499-509 
and Lee, W. (1987) Mol.  Cell. Biol. 7, 1697-1709 
20. Guiochon-Mantel, A,, Loosfelt, H., Lescop, P., Sar, S . ,  Atger, M., Pemot-Ap- 
21. Guiochon-Mankl. A,. Lemu, P., Christin-Maitre, S . .  Loosfelt, H., Pernot-Ap- 
Chem. 267,968-974 
planat, M., and  Milgrom, E. (1989) Cell 67, 1147-1154 
22. King, W. J., and  Greene,  G. L. (1984) Nature 307,745-747 
23. Welshons, W. V.,  Lieberman, M. E., and  Gorski, J. (1984) Nature 307,747-749 
24. Perrot-Applanat,  M.,  Logeat, F., Groyer-Picard, M. T., and  Milgrom, E. (1985) 
25. Elashry-Stowers, D., Zava, D. T., Speers, W. C., and Edwards, D. P. (1988) 
26. Andersson, S., Davis, D. L., Dahlback, H., Jornvall, H., and Russell, D. W. 
planat, M., and  Milgrom; E. (1991) EMBO J.  10,3851-3859 
Endocrinology 116, 1473-1484 
Cancer Res. 48,6462-6474 
27. Yarbrough, W. G., Quarmby, V. E., Simental, J. A., Joseph, D. R., Sa& M., 
(1989) J. Biol. Chem. 264,82224229 
Lubahn.  D. B.. Olsen  K. L.. French. F. S . .  and  Wilson. E. M. (1990) J.  B i d .  
Bipartite Nuclear Targeting Signal  in the Androgen Receptor 13123 
28. Tan, J. A., Joseph, D.  R., Quarmby, V. E., Lubahn, D. B.,  Sar, M., French, F. S., 
29. Quarmby, V. E., Kemppainen, J. A,,  Sar, M., Lubahn, D. B.,  French, F. S., and 
30. Freedman, L. P. (1992) Endocr. Rev. 13,  129-145 
31. Wong,  C. I., Zhou, 2. X., Sar., M., and Wilson, E. M. (1993)J. Biol. Chem. 268, 
32. Roberts, B. L.,, Richardson, W. D., and  Smith, A. E. (1987) Cell 50,465475 
33. Chandran, U. R., and  DeFranco, D. B. (1992) Mol. Endocrinol. 6,837-844 
34. Rihs, H. P., Jans, D. A., Fan, H., and  Peters, R. (1991) EMBO J .  10, 633439 
35. Rihs, H. P., and  Peters, R. (1989) EMBO J. 8, 1479-1484 
36. Moll, T., Tebb, G., Surana, U., Robitsch, H., and  Nasmyth, K. (1991) Cell 66, 
37. DeFranco, D. B.,  Qi, M., Borror, K. C.,  Garabedian, M. J., and  Brautigan, D.  L. 
743-758 
38. Zhou, 2. X., Wong, C. I., Sar, M., and Wilson, E. M. (1994)Rec. Prog. Horm. Res. 
(1991) Mol. Endocrinol. 5, 1215-1228 
39. Sanchez, E. R., Hirst, M., Schemer, L. C. ,  Tang, H. Y., Welsh, M. J.,  Harmon, 
49,249-274 
J. M., Simons, S. S., Ringold, G. M., Pratt, W. B. (1990) J.  Bid. Chem. 266, 
20123-20130 
40. Martins, V R., Pratt, W. B., Terracio, L., Hirst, M. A,. Ringold, G. M., and 
Housley, P. R. (1991) Mol. Endocrinol. 5,217-225 
41. Ylikomi, T., Bocquel, M. T., Berry, M., Gronemeyer, H., and Chambon, E? (1992) 
EMBO J .  11,36814694 
42. Dingwall,  C., and Laskey, R. (1992) Science 258, 942-947 
43. Richardson, W. D., Mills, A. D., Dilworth, S. M., Laskey, R. A,, and Dingwall, 
44. Akey, C. W., and Goldfarb, D. S. (1989) J. Cell Bid. 109,971-982 
45. Feldherr,  C. M., and Akin, D. (1990) J. Cell Biol. 111, 1-8 
46. Newmeyer, D. D., and  Forbes, D. J .  (1988) Cell 52,  641-653 
and Wilson, E. M. (1988) Mol. Endoerinol. 2, 12761285 
Wilson, E. M. (1990) Mol. Endocrinol. 4,  1399-1407 
19004-19012 
C. (1988) Cell 62,655464 
47. Breeuwer, M., and Goldfarb, D. S. (1990) Cell 60,999-1008 
48. Finlay, D. R.. Meier, E., Bradley, P., Horecka,  J.,  Forbes, D. J. (1991) J. Cell 
49. Benditt, J. O., Meyer, C., Fasold,  H.,  Barnard, F. C.,  and Riedel, N. (1989)Proc. 
50. Adam, S. A,, and Gerace, L. (1991) Cell 66,837-847 
51. Stochaj, U., Osbome, M., Kurihara, T., and  Silver, P. (1991) J. Cell Bid. 113, 
1243-1254 
52. Schowalter, D. B., Sullivan, W. P., Maihle,  N. J., Dobson, A. D. W., Conneely, 0. 
M.,  O'Malley,  B.  W., and TOR, D. 0. (1991) J. Bwl. Chem. 266,21165-21173 
53. Onate, S. A., Estes, P. A,, Welch, W. J . ,  Nordeen, S. K., and  Edwards, D. P. 
(1991) Mol. Endmrinol. 5, 1993-2004 
54. Catelli, M. G., Binart, N., Jung-Testas, I., Renoir, J. M., Baulieu,  E. E., Fera- 
misco, J. R., and Welch, W. J. (1985) EMBO J. 4,  3131-3135 
55. Kost, S. L., Smith, D. F., Sullivan, W. P., Welch, W. J.,  and Toft, D. 0. (1989) 
Mol. Cell. Biol. 9, 3829-3838 
56. Sanchez,  E. R., Tuft, D. O., Schlesinger, M. J.,  and  Pratt, W. B. (1985) J. Bid. 
Chem. 260,1239%12401 
57. Cadepond, F., Schweizer-Groyer, G., Segard-Maurel, I., Jibard, N., Hollenberg, 
S. M., Giguere, V, Evans, R. M., and  Baulieu,  E. E. (1991) J. Biol. Chem. 
266,58344841 
Biol. 114,  169-183 
Natl. Acad. Sci. U. S .  A. 86,9327-9331 
58. Hunt, T. (1989) Cell 59, 949-951 
59. Row, P., Blanchard, J. M., Fernandez, A., Lamb,  N.,  Jeanteur, P., and Piec- 
haczyk, M. (1990) Cell 63,341-351 
60. Lubahn, D. B.,  Joseph, D. R., Sar, M., Tan, J. A,, Higgs, H. N., Larson, R. E., 
French, F. S., and Wilson, E. M. (1988) Mol. Endoerinol. 2,  1265-1275 
61. Lubabn, D. B., Brown, T. R., Simental, J. A,, Higgs, H. N., Migeon, C. J., 
Wilson, E. M.,  and  French, F. S. (1989) Proc. Natl. Amd. Sci. U. S. A. eS, 
9534-9538 
